KLK3 and prostate carcinoma: Guidelines currently recommend shared decision-making between males and their health care clinicians regarding prostate cancer screening using prostate-specific antigen (PSA), taking into consideration patient age and life expectancy.1 However, it is unclear the extent to which life expectancy is associated with screening practices among older males.